Quality of Life and the Psychiatric Status of Individuals Treated With GH in Childhood
Brian Stabler Natalie C. Frank The University of North Carolinaat Chapel Hill George Washington University
Measures of quality of life (QOL) have been helpful in assessing patients with growth hormone deficiency (GHD) because these patients experience significant sources of stress and dysfunction both during childhood and over their lifespan, even after medical therapy is completed. Growth delay, short stature, and its accompanying psychosocial stressors have been the subject of much investigation by behavioral specialists ( Stabler & Under wood , 1986, 1994). Several studies have illustrated the extent of dissatisfaction with life circumstance reported by many individuals with GHD ( Bjork, Jonsson Westphal, & Levin, 1989; Clopper, MacTaggart, Mazur, Voorhees, & Mills, 1986; Dean, 1990; Dean, McTaggart, Fish, & Friesen, 1986; Mitchell, Johnsen, Joyce, Libber, Plotnik, Migeon, & Blizzard, 1986). Nevertheless, there is little evidence that this body of knowledge has found its way into the everyday practice repertoire of clinical pediatric endocrinologists. Unless this picture changes, we may anticipate a continuing rate of disappointing psychosocial outcomes for a significant
Questia, a part of Gale, Cengage Learning. www.questia.com
Publication information: Book title: Measuring Health-Related Quality of Life in Children and Adolescents:Implications for Research and Practice. Contributors: Dennis Drotar - Editor. Publisher: Lawrence Erlbaum Associates. Place of publication: Mahwah, NJ. Publication year: 1998. Page number: 273.
This material is protected by copyright and, with the exception of fair use, may not be further copied, distributed or transmitted in any form or by any means.